BioVie, Inc. (BIVI)
1.625
+0.02
(+0.93%)
USD |
NASDAQ |
Sep 21, 16:00
1.625
0.00 (0.00%)
After-Hours: 20:00
BioVie Enterprise Value : 3.442M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 3.442M |
| September 17, 2026 | 4.724M |
| September 16, 2026 | 4.271M |
| September 15, 2026 | 4.498M |
| September 14, 2026 | 6.760M |
| September 11, 2026 | 5.855M |
| September 10, 2026 | 5.704M |
| September 09, 2026 | 6.157M |
| September 08, 2026 | 6.911M |
| September 04, 2026 | 6.383M |
| September 03, 2026 | 6.610M |
| September 02, 2026 | 6.610M |
| September 01, 2026 | 8.193M |
| August 31, 2026 | 8.495M |
| August 28, 2026 | 7.59M |
| August 27, 2026 | 7.816M |
| August 26, 2026 | 7.213M |
| August 25, 2026 | 7.062M |
| August 24, 2026 | 7.439M |
| August 21, 2026 | 6.006M |
| August 20, 2026 | 5.327M |
| August 19, 2026 | 1.405M |
| August 18, 2026 | -1.428M |
| August 17, 2026 | 0.1228M |
| August 14, 2026 | 1.858M |
| Date | Value |
|---|---|
| August 13, 2026 | 3.064M |
| August 12, 2026 | 3.064M |
| August 11, 2026 | 0.8771M |
| August 10, 2026 | -0.4051M |
| August 07, 2026 | -1.165M |
| August 06, 2026 | 1.480M |
| August 05, 2026 | 6.685M |
| August 04, 2026 | 5.101M |
| August 03, 2026 | 3.517M |
| July 31, 2026 | 2.763M |
| July 30, 2026 | 2.084M |
| July 29, 2026 | 0.8017M |
| July 28, 2026 | 1.330M |
| July 27, 2026 | 1.631M |
| July 24, 2026 | 1.631M |
| July 23, 2026 | 2.159M |
| July 22, 2026 | 1.405M |
| July 21, 2026 | 1.028M |
| July 20, 2026 | 2.046M |
| July 17, 2026 | 4.875M |
| July 16, 2026 | 4.271M |
| July 15, 2026 | 4.648M |
| July 14, 2026 | 3.215M |
| July 13, 2026 | 3.668M |
| July 10, 2026 | 8.420M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 599.19M |
| Amgen, Inc. | 251.80B |
| Anika Therapeutics, Inc. | 265.34M |
| BioCryst Pharmaceuticals, Inc. | 2.699B |
| Imunon, Inc. | 7.326M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.646M |
| Total Expenses (Quarterly) | 5.646M |
| EPS Diluted (Quarterly) | -0.7485 |
| Earnings Yield | -196.8% |
| Normalized Earnings Yield | -196.76 |